On #WorldCancerDay, we highlight the vital role of cancer research in providing patients early access to innovative treatments and generating critical insights that advance medical progress. At Lambda Therapeutic Research and Novum Pharmaceutical Research Services, we’re honored to partner with global biotech and pharmaceutical companies to support these life-changing studies, working together for a future with better outcomes for cancer patients.
Cancer and World Cancer Day
Cancer remains a major global health challenge, encompassing hundreds of diseases characterized by uncontrolled cell growth and spread. In 2022, approximately 20 million new cancer cases were diagnosed, and 9.7 million people worldwide lost their lives to the disease. By 2050, the number of cancer cases is projected to rise to 35 million due to population growth alone. Cancer is also the leading or second-leading cause of premature death (before age 70) in 112 countries.
Lung cancer remains the most commonly diagnosed cancer and the leading cause of cancer-related deaths worldwide, accounting for nearly 2.5 million cases (1 in 8 cancers) and 1.8 million deaths (1 in 5 cancer deaths). Among males, lung cancer is followed by prostate, colorectal, and stomach cancers in incidence, and liver, colorectal, and stomach cancers in mortality. In females, breast cancer ranks first for both incidence and mortality, followed by lung, colorectal, and cervical cancers.
Observed annually on February 4, World Cancer Day brings people together globally to raise awareness, improve education, and inspire collective action against this life-threatening disease. The theme for 2025-2027, “United by Unique,” emphasizes patient-centered care and explores new ways to drive meaningful change. This theme aligns with our mission at Lambda & Novum, where we strive to personalize and optimize the clinical trial experience, recognizing each patient’s unique needs and circumstances. By working together, united in purpose, we can make significant strides toward a future with better outcomes for all cancer patients.
Cancer research: Hope for the Future
Clinical trials play a pivotal role in the advancement of cancer treatment and understanding the disease’s diverse forms. Every aspect of a trial—from patient-friendly protocols to engagement strategies—is carefully designed to prioritize patient well-being and encourage participation. At Lambda & Novum, we share this commitment, navigating the complexities of clinical research to help bring life-changing therapies to those who need them most.
On World Cancer Day—and every day—we remain dedicated to applying our expertise to bridge gaps in care and move closer to a future free from cancer.
Advancing Oncology Clinical Trials
We understand that participating in a clinical trial can be a complex and sometimes daunting experience for cancer patients. That’s why we prioritize a patient-centric approach in everything we do.
Strategic Site Selection
Selecting the right clinical trial sites is crucial for the success of cancer clinical trials. We prioritize this process, focusing on experienced investigators and site staff well-versed in clinical oncology, especially in treating cancer. These carefully chosen sites ensure optimal data collection and a smoother trial experience for recruited patients.
Streamlining Recruitment & Retention
Enhancing trial success, we employ patient-centric initiatives and care coordinators, addressing barriers for a supportive participant experience. Recruitment and retention challenges are effectively tackled through these coordinators’ close work with participants, leading to improved patient outcomes and better data collection.
Innovative Trial Protocols
Innovation is at the heart of our trial protocols, ensuring a patient-centric experience. We design innovative and patient-friendly protocols that enhance the trial journey. By incorporating the latest advancements and considering the unique needs of cancer patients, we strive for improved outcomes and seamless data collection.
Overcoming the Complexities of Oncology Clinical Trials
At Lambda & Novum, our commitment to advancing cancer treatment is reflected in our extensive experience in oncology clinical trials. With a strong portfolio that includes over 265 clinical trials spanning 15+ therapeutic areas, oncology remains a cornerstone of our expertise.
68
Oncology Trials
5100+
Patients
1000+
Global Sites
Lambda has a proven track record in cancer clinical trials, having conducted 68 studies across a range of indications. Our expertise spans common cancers such as breast cancer (including metastatic and triple-negative), lung cancer (NSCLC), and prostate cancer, as well as complex and less common cancers, including ovarian, gastric, and bladder cancers. Additionally, we have experience in hematological malignancies (such as lymphoma and myelodysplastic syndrome), pediatric cancers, and various other conditions related to cancer or its treatment.
With experience enrolling over 5100 patients across a network of 1000+ sites, we efficiently manage large-scale, complex trials while upholding the highest standards of patient care and data integrity. Our expertise also extends to biosimilar development, where we have significant experience with key oncology therapies, including Bevacizumab, Denosumab, Trastuzumab, Pertuzumab, Rituximab, and Trastuzumab Emtansine.
Our end-to-end capabilities—including medical imaging, biostatistics, bioanalytical & pharmacovigilance services—allow us to provide comprehensive solutions for our clients. By maintaining the highest standards of quality and regulatory compliance, we ensure reliable, high-quality trial outcomes. Our successful regulatory submissions to the USFDA, EMA, and ANVISA highlight our deep understanding of global regulatory frameworks and our expertise in navigating the complexities of the approval process.
Transform Your Oncology Trials with Our Proven Expertise
Explore Our Success Stories:
At Lambda and Novum, we navigate the complex clinical trial landscape, leveraging our extensive expertise, bringing hope, and accelerating breakthroughs for patients. Leverage Lambda & Novum’s extensive experience & proven track record to accelerate your Oncology clinical trials. Get in touch with our team of experts. Let’s make Progress together in the Fight Against Cancer.
About Lambda
Lambda & Novum delivers comprehensive, end-to-end clinical research services to the innovator, biotech, and generic pharmaceutical industries worldwide. With a strong global presence in India, the USA, Canada, the UK, Spain and Poland, we bring specialized expertise to every project. Our focus on secure IT infrastructure and automation ensures timely project delivery and strict adherence to international regulatory standards. Lambda’s exemplary regulatory track record includes over 60 successful inspections and audits by esteemed authorities, including the USFDA, EMEA, MHRA, EU member states, and other global regulatory bodies, in the past five years.
Lambda’s commitment to excellence has garnered significant recognition, including the ‘Best Indian CRO’ award from Frost & Sullivan (USA) and the ‘Great Indian Workplace’ title from UBS Transformance. Recent accolades include the ‘Regulatory Excellence’ Award at the CPhI Pharma Awards 2023 and the ‘Industry Partner of the Year’ Award at the Global Generics & Biosimilar Awards 2023.
